Apollomics Inc.

Apollomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies, particularly targeting difficult-to-treat and treatment-resistant cancers ¹. The company's strategic approach involves both targeted and immuno-oncology methods to address various cancer indications, including acute myeloid leukemia, lung cancer, and brain cancer ². Apollomics employs a biomarker-driven diagnostic approach for patient screening to enhance precision in identifying patients who may benefit from targeted therapy ³.

The core business model of Apollomics is centered on the research, development, and potential commercialization of novel oncology therapies ⁴. The company generates revenue primarily through collaboration and licensing arrangements, rather than direct product sales, as it currently has no products approved for commercial sale ⁵. Its primary customer segments, once products are approved, would be patients with specific cancer indications, with a focus on those with unmet medical needs ⁶. The company's strategy includes seeking development and commercialization partnerships to optimize efficiency and maximize market potential ⁷.

Apollomics' product candidate pipeline is categorized into two groups based on their mechanisms of action: tumor inhibitors and immuno-oncology drugs ⁸. The tumor inhibitor group includes two small molecule inhibitors: vebreltinib (APL-101) and APL-102 ⁹. Vebreltinib, the most advanced product candidate, is a potent, oral, highly selective c-Met inhibitor being investigated as a single agent for NSCLC and other advanced tumors with c-Met alterations, and as a combination therapy with EGFR inhibitors ¹⁰. Avistone, Apollomics' partner in China, has received conditional approval from the NMPA for vebreltinib for NSCLC with Met Exon 14 skipping in November 2023 ¹¹, for gliomas with a PTPRZ1-MET fusion gene in April 2024 ¹², and for MET-amplified NSCLC in June 2025 ¹³. Apollomics retains exclusive rights to vebreltinib outside China, Hong Kong, and Macau ¹⁴. APL-102 is also a tumor inhibitor, with Apollomics holding worldwide rights ¹⁵.

The immuno-oncology product candidates include APL-501, APL-502, and APL-801 ¹⁶. APL-501 is an anti-PD-1 antibody product candidate, with Apollomics retaining global rights outside China, where Genor is developing it ¹⁷. APL-502 is an anti-PD-L1 antibody product candidate, with Apollomics holding global rights ex-China, while CTTQ is developing it in China ¹⁸. CTTQ's APL-502 has been approved by China's NMPA for three indications: extensive-stage small cell lung cancer, recurrent/metastatic endometrial cancer, and late-stage unresectable or metastatic renal cell carcinoma ¹⁹. APL-801 is an early-stage candidate related to antibodies against CD40, developed through a partnership with RevMab ²⁰.

For the fiscal year ended December 31, 2025, Apollomics reported net losses of $10.9 million ²¹. The company used $10.4 million in net cash for operating activities ²². As of December 31, 2025, the balance of cash and cash equivalents was $3.3 million ²³. The company's intangible asset for the uproleselan program was written down by an impairment loss of $10.0 million ²⁴.

In May 2024, GlycoMimetics, the licensor of uproleselan in China, announced negative results from its pivotal Phase 3 study, leading Apollomics to close its own Phase 3 bridging study in China early ²⁵. Consequently, Apollomics terminated its exclusive collaboration and license agreement with GlycoMimetics in February 2025, effective May 2025 ²⁶. In November 2024, Apollomics also terminated the license for APL-810 with TYG, effective January 2025, as part of pipeline prioritization ²⁷. On December 11, 2025, Apollomics formally terminated the Development and License Agreement for APL-122 with Edison Oncology Holding Corporation, citing material breaches by Edison ²⁸. In late August 2025, the company's former management announced the expected discontinuation of all activities related to the SPARTA clinical trial due to severe cash constraints ²⁹. However, following a $4.1 million PIPE financing on September 3, 2025, and the appointment of a new Board of Directors and executive management team, the company reversed its wind-down plans and is continuing the global Phase 2 trial of APL-101 (vebreltinib) ³⁰. The company also entered into a definitive settlement agreement regarding a lawsuit with two minority investors, requiring a total payment of $5.0 million in settlement installments plus approximately $0.9 million in legal fees over 24 months ³¹.

Apollomics anticipates that it will continue to incur net losses and net operating cash outflows for the foreseeable future and may never achieve or maintain profitability ³². The company's existing cash resources of $3.3 million as of December 31, 2025, are not sufficient to meet its obligations through April 30, 2027, even after factoring in the expected receipt of a $2.3 million outstanding receivable balance from LaunXP International ³³. Subsequent to year-end, on March 30, 2026, liquidity was further supported by a $2.0 million unsecured convertible bridge loan from Mr. Hung-Wen (Howard) Chen, the Chairman and CEO ³⁴. The company will require additional capital, which it expects to seek through equity or debt financings or strategic partnerships ³⁵.

A major growth area for Apollomics is the global development of vebreltinib, aiming to expand its potential across different c-Met alterations and tumor types ³⁶. The company is developing vebreltinib for NSCLC with Met Exon 14 skipping, NSCLC with c-Met amplification, and pan-tumor c-Met fusions, including brain tumors with c-Met alterations ³⁷. The primary focus for future vebreltinib clinical development will be for the treatment of NSCLC with c-Met Amplification ³⁸. Apollomics is also exploring combination therapy using vebreltinib with an EGFR inhibitor in an investigator-sponsored study to reduce treatment resistance ³⁹. The company plans to pursue marketing authorizations in the United States for NSCLC with Met Exon 14 skipping and NSCLC with c-Met amplification based on clinical results from the APL-101-01 (SPARTA) study and Avistone's Phase 2 study, following pre-NDA meetings with the FDA upon data maturation ⁴⁰. A similar approach is intended for regulatory approval in the E.U. and other non-U.S. countries ⁴¹. In 2026, discussions with the EMA are planned regarding the approvability of vebreltinib for GBM with PTPRZ1-MET fusion ⁴².

Another growth area involves expanding the drug portfolio through collaborations and partnerships, actively seeking opportunities to in-license new assets and explore combination therapies to increase therapeutic benefit ⁴³. The company also plans to seek strategic partnerships with recognized industry players for development and commercialization to make innovative medicines accessible and maximize market potential efficiently ⁴⁴.

Operationally, Apollomics implemented cost reduction initiatives beginning in early 2024, prioritizing the development of vebreltinib and uproleselan, and reducing other operating expenses through pipeline prioritization and employee reductions ⁴⁵. The company has decreased the size and capabilities of its organization, transitioning significant operational functions to Taiwan while reducing headcount in China ⁴⁶. As of December 31, 2025, the company had 14 full-time employees ⁴⁷.

Regarding capital allocation, Apollomics has paid $590,000 under the RevMab Agreement through 2025, including a $300,000 upfront payment ⁴⁸. The company incurred developmental expenses of nil in 2019, $140,000 in 2021, $150,000 in 2022, and nil in each of the years 2023 through 2025 for this agreement ⁴⁹. Apollomics will also pay RevMab a royalty rate of 2% of net sales of mAb Products, subject to adjustment ⁵⁰. In September 2025, the company issued 1.04 million Class A Ordinary Shares in a private placement at $3.9317 per share, generating aggregate gross proceeds of $4.1 million ⁵¹. The $2.0 million convertible bridge loan from the CEO on March 30, 2026, will automatically convert into equity securities upon the closing of the next equity financing that raises at least $10,000,000, with a conversion price equal to 80% of the lowest per-share purchase price paid by investors in that financing ⁵².

Apollomics faces structural headwinds and execution risks, including the need for substantial additional capital to finance operations, which may not be available on acceptable terms ⁵³. The company's dependence on the success of vebreltinib is a significant risk, as failure to obtain approval or delays would materially harm the business ⁵⁴. Difficulties in patient enrollment in clinical trials, such as the vebreltinib SPARTA trial, have been experienced, partly due to requirements for non-standard genetic testing ⁵⁵. As of March 31, 2026, only six patients had been enrolled in the NSCLC with Met amplification cohort in the last nine months ⁵⁶. This led to the indefinite deferral of the U.S. NDA filing for vebreltinib for NSCLC with MET exon 14 skipping and a strategic pivot to narrow the development focus ⁵⁷. The company is also subject to an ongoing litigation with Medpace, Inc., a clinical research organization, which sued Apollomics for allegedly unpaid service fees, and Apollomics has filed an Amended Counterclaim seeking in excess of $2.0 million ⁵⁸.

Apollomics faces material risks including its status as a pre-revenue biotechnology company with a history of losses, requiring substantial additional capital that may not be available on acceptable terms, or at all, which could force delays or elimination of development programs ⁵⁹. The company is substantially dependent on the success of vebreltinib, its most advanced product candidate, and failure to obtain regulatory approval or significant delays would materially harm the business ⁶⁰. Clinical trials, including those for vebreltinib, may fail to adequately demonstrate safety, efficacy, and risk/benefit, leading to delays or prevention of regulatory approval and commercialization ⁶¹. For example, in May 2024, negative Phase 3 results for uproleselan from its licensor led to an impairment loss of $10.0 million to write down the full value of the intangible asset for that program ⁶². Patient enrollment in clinical trials, such as the vebreltinib SPARTA trial, has been challenging, with only six patients enrolled in a specific cohort in the last nine months as of March 31, 2026, contributing to the indefinite deferral of the U.S. NDA filing for vebreltinib for NSCLC with MET exon 14 skipping ⁶³. The company is also involved in active litigation with Medpace, Inc., where an unfavorable judgment or inability to recover damages under its counterclaim for over $2.0 million could severely harm its financial condition ⁶⁴. Operations in China are subject to complex and rapidly evolving laws and regulations, including government control of currency conversion and potential intervention in business operations, which could restrict funding and expansion ⁶⁵. Cybersecurity and data protection laws in China, as well as restrictions on transferring scientific data or drug products abroad, pose additional risks ⁶⁶. Deterioration of trade relations between the United States and China, and political relationships among Greater China and other countries, may also adversely affect business operations and collaboration prospects ⁶⁷. The company's intellectual property rights are subject to challenges, narrowing, circumvention, or invalidation by third parties, and the cost and time associated with protecting these rights can be substantial ⁶⁸. The trading price of Apollomics' securities has been and is likely to continue to be volatile, which could result in substantial losses to holders ⁶⁹.

Management's message to shareholders emphasizes the company's strategic focus on developing novel therapies for difficult-to-treat cancers and drug-resistant patients, aiming to unlock treatment synergies and address drug resistance ⁷⁰. Despite recent operational challenges, including a complete transition of executive leadership and Board of Directors in August and September 2025, the new management team has reversed prior wind-up plans and is continuing operations ⁷¹. A key strategic priority is advancing the global development of vebreltinib to expand its potential across different c-Met alterations and tumors, with a primary focus on NSCLC with c-Met Amplification ⁷². Management also prioritizes expanding the drug portfolio through collaborations and partnerships, actively seeking opportunities to in-license new assets and explore combination therapies ⁷³. Furthermore, the company aims to seek development and commercialization partnerships to optimize efficiency and maximize market potential ⁷⁴. Management acknowledges the need for additional capital, expecting to seek it through equity or debt financings or strategic partnerships, and has secured a $2.0 million unsecured convertible bridge loan from the Chairman and CEO on March 30, 2026, to support liquidity ⁷⁵.